MCID: MLG039
MIFTS: 29

Malignant Essential Hypertension malady

Categories: Genetic diseases, Cardiovascular diseases, Blood diseases, Rare diseases

Aliases & Classifications for Malignant Essential Hypertension

About this section

Aliases & Descriptions for Malignant Essential Hypertension:

Name: Malignant Essential Hypertension 11 13 68
 
Accelerated Essential Hypertension 11

Classifications:



External Ids:

Disease Ontology11 DOID:10823
ICD9CM32 401.0
SNOMED-CT62 1218009, 78975002
NCIt45 C34802

Summaries for Malignant Essential Hypertension

About this section
MalaCards based summary: Malignant Essential Hypertension, also known as accelerated essential hypertension, is related to congenital pulmonary airway malformation and adult-onset multiple mitochondrial dna deletion syndrome due to dguok deficiency. An important gene associated with Malignant Essential Hypertension is KLKB1 (Kallikrein B1), and among its related pathways is Agents Acting on the Renin-Angiotensin System Pathway, Pharmacodynamics.

Related Diseases for Malignant Essential Hypertension

About this section

Diseases in the Familial Hypertension family:

Hypertension, Essential Hypertension, Essential 7
Hypertension, Essential 8 malignant essential hypertension
Malignant Hypertension Benign Essential Hypertension
Benign Secondary Hypertension Malignant Secondary Hypertension

Diseases related to Malignant Essential Hypertension via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 53)
idRelated DiseaseScoreTop Affiliating Genes
1congenital pulmonary airway malformation10.3AGTR2, REN
2adult-onset multiple mitochondrial dna deletion syndrome due to dguok deficiency10.3HBB, HBD
3middle ear adenoma10.3HBB, HBD
4costello syndrome10.2HBB, HBD
5extrahepatic bile duct papillary adenoma10.2HBB, HBD
6endometrial adenocarcinoma10.2HBB, HBD
7gaba-transaminase deficiency10.2HBB, HBD
8mixed fibrolamellar hepatocellular carcinoma10.2HLA-A, TNFRSF25
9intracranial structure hemangioma10.2HBB, HBD
10hypopharynx cancer10.2HLA-A, TNFRSF25
11artemis deficiency10.2KLKB1, KNG1
12malignant otitis externa10.1REN, TNFRSF25
13idiopathic panuveitis10.1ACE, AGTR2
14hypotrichosis simplex10.1ACE, REN
15rheumatic fever10.1KNG1, TNFRSF25
16hyperinsulinemic hypoglycemia, familial, 310.1ACE, REN
17carbohydrate metabolic disorder10.1ACE, REN
18leukocyte adhesion deficiency, type iii10.1KLK4, KLKB1, KNG1
19hypothyroidism, congenital nongoitrous, 510.1ACE, REN
20hypogonadism mitral valve prolapse mental retardation10.1ACE, REN
21listeriosis10.1ACE, REN
22dientamoebiasis10.1ACE, REN
23lymph node cancer10.1ENSG00000264813, KNG1
24iris disease10.0ACE, REN
25preaxial polydactyly of fingers10.0ACE, AGTR2
26prostate neuroendocrine neoplasm10.0ACE, REN
27cascade stomach10.0ACE, REN
28tuberculous pneumothorax10.0ACE, ENSG00000264813
29hyperuricemic nephropathy, familial juvenile 210.0ACE, REN
30hemorrhoid10.0ENSG00000264813, REN
31mesenteric lymphadenitis10.0ACE, ENSG00000264813
32diffuse pulmonary fibrosis10.0ACE, SAMHD1
33omsk hemorrhagic fever10.0HLA-A, KLK4
34microphthalmia, isolated, with coloboma 710.0ACE, AGTR2, REN
35eastern equine encephalitis9.9ACE, REN
36juvenile amyotrophic lateral sclerosis with dementia9.9ACE, ENSG00000264813
37myopia9.9ACE, REN
38flat umbilicus familial9.9ACE, REN
39secretory diarrhea myopathy and deafness9.9ACE, KNG1
40opiate dependence9.9ACE, SAMHD1
41peroneal neuropathy9.9ACE, REN, TNFRSF25
42congenital nystagmus9.9ACE, ENSG00000264813, REN
43mechanical ectropion9.9ACE, KLKB1, KNG1
44red-green color blindness9.8ACE, SAMHD1, TNFRSF25
45critical limb ischemia9.8ACE, KNG1, REN
46hepatic infarction9.8AGTR2, HBB, HBD, KNG1, REN
47pyrimidine metabolic disorder9.7ACE, KNG1, REN
48petrositis9.7ACE, KLKB1, KNG1, REN
49diabetes mellitus, insulin-dependent, 209.6ACE, HLA-A, REN, TNFRSF25
50arteriosclerosis9.6

Comorbidity relations with Malignant Essential Hypertension via Phenotypic Disease Network (PDN):

(show all 38)
Anxiety DisorderDeficiency Anemia
Hypertensive RetinopathyHypothyroidism
Iron Deficiency AnemiaActive Peptic Ulcer Disease
Acute CystitisAcute Kidney Failure
Basilar Artery InsufficiencyBenign Essential Hypertension
BronchitisCerebral Atherosclerosis
Cerebrovascular DiseaseChronic Kidney Failure
Chronic Myocardial IschemiaEpilepsy, Focal, with Speech Disorder and with or Without Mental Retardation
EsophagitisFamilial Atrial Fibrillation
First-Degree Atrioventricular BlockGeneralized Atherosclerosis
Heart DiseaseHypertension, Essential
Hypertensive EncephalopathyIntermediate Coronary Syndrome
Intracranial ThrombosisIschemic Heart Disease
Kidney DiseaseLeft Ventricular Outflow Tract Obstruction
Malignant Renovascular HypertensionMitral Valve Disease
Peripheral Vascular DiseaseRenal Artery Atheroma
Respiratory FailureSinoatrial Node Disease
Swallowing DisordersTransient Cerebral Ischemia
Vertebral Artery InsufficiencySchizophreniform Disorder

Graphical network of the top 20 diseases related to Malignant Essential Hypertension:



Diseases related to malignant essential hypertension

Symptoms & Phenotypes for Malignant Essential Hypertension

About this section

Drugs & Therapeutics for Malignant Essential Hypertension

About this section

Drugs for Malignant Essential Hypertension (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 7)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
VerapamilapprovedPhase 213052-53-92520
Synonyms:
(+-)-Verapamil
(+/-)-VERAPAMIL
(1)-3-(3,4-Dimethoxyphenyl)-6-((5,6-dimethoxyphenethyl)methylamino)hexane-3-carbonitrile
2-(3,4-Dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethyl-methyl-amino]-2-(1-methylethyl) pentanenitrile
2-(3,4-dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethyl-methylamino]-2-propan-2-ylpentanenitrile
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile
5-((3,4-Dimethoxyphenethyl)methylamino)-2-(3,4-dimethoxyphenyl)-2-isopropylvaleronitrile
5-[(3,4-Dimethoxyphenethyl)methylamino]-2-(3,4-dimethoxyphenyl)-2-isopropylvaleronitrile
52-53-9
56949-77-0
AB00053495
AC-16016
AC1L1DV5
Akilen
Anpec
Apo-Verap
Arpamyl
Arpamyl LP
BPBio1_000268
BRD-A09533288-001-02-7
BRD-A09533288-003-05-6
BSPBio_000242
BSPBio_001513
BSPBio_002358
Berkatens
Bio-0754
Bio1_000425
Bio1_000914
Bio1_001403
Bio2_000233
Bio2_000713
C07188
C27H38N2O4
CCRIS 6749
CHEBI:9948
CHEMBL6966
CID2520
CP-16533-1
CP-165331
Calan
Calan SR
Calan sr
Calaptin
Calaptin 240 SR
Calcan
Cardiabeltin
Cardiagutt
Cardibeltin
Cardioprotect
Caveril
Civicor
Civicor Retard
Coraver
Cordilox
Cordilox SR
Corpamil
Covera-HS
Covera-Hs
Covera-hs
D-365
D02356
DB00661
Dexverapamil
Dignover
Dilacoran
Dilacoran HTA
DivK1c_000399
Drosteakard
Durasoptin
EINECS 200-145-1
EINECS 260-462-6
Elthon
FT-0080127
Falicard
Finoptin
Flamon
Geangin
HMS1791L15
HMS1989L15
HMS2089H17
Harteze
Hexasoptin
Hexasoptin Retard
Hormitol
I06-0063
IDI1_000399
IDI1_033983
Ikacor
Ikapress
Inselon
Iproveratril
Isoptimo
Isoptin
Isoptin Retard
Isoptin SR
Isoptin sr
Isoptine
Isoptino
Isotopin
Izoptin
Jenapamil
KBio1_000399
KBio2_000233
KBio2_002343
KBio2_002801
KBio2_004911
KBio2_005369
KBio2_007479
KBio3_000465
KBio3_000466
 
KBio3_002823
KBioGR_000233
KBioGR_001372
KBioGR_002343
KBioSS_000233
KBioSS_002346
L001330
LS-174
Lekoptin
Lodixal
Lopac0_001237
Magotiron
Manidon
Manidon Retard
MolPort-000-721-258
NCGC00016083-14
NCGC00024710-04
NCGC00024710-05
NCGC00024710-06
NCGC00024710-07
NCGC00024710-08
NCGC00024710-09
NCI60_020143
NINDS_000399
NSC272366
NU-Verap
Novapamyl LP
Novo-Veramil
Nu-Verap
Ormil
Praecicor
Prestwick0_000141
Prestwick1_000141
Prestwick2_000141
Prestwick3_000141
Quasar
Rapam
Robatelan
SPBio_001820
SPBio_002181
STK538085
Securon
Spectrum2_001740
Spectrum4_000906
Spectrum5_001786
Tarka
UNII-CJ0O37KU29
Univer
Univex
VERAPAMIL
Vasolan
Vasomil
Vasopten
Vera-Sanorania
Verabeta
Veracaps SR
Veracim
Veracor
Verahexal
Veraloc
Veramex
Veramil
Verapamil
Verapamil (USAN/INN)
Verapamil AL
Verapamil Acis
Verapamil Atid
Verapamil Basics
Verapamil Ebewe
Verapamil HCl
Verapamil Henning
Verapamil Injection
Verapamil MSD
Verapamil NM
Verapamil NM Pharma
Verapamil Nordic
Verapamil PB
Verapamil Riker
Verapamil SR
Verapamil Verla
Verapamil [USAN:BAN:INN]
Verapamil [USAN:INN:BAN]
Verapamil [Usan:Ban:Inn]
Verapamil-AbZ
Verapamilo
Verapamilo [INN-Spanish]
Verapamilum
Verapamilum [INN-Latin]
Verapin
Verapress 240 SR
Veraptin
Verasal
Verasifar
Veratensin
Verdilac
Verelan
Verelan PM
Verelan SR
Verexamil
Veroptinstada
Verpamil
Vetrimil
Vortac
Vérapamil
alpha-((N-Methyl-N-homoveratryl)-gamma-aminopropyl)-3,4-dimethoxyphenylacetonitrile
alpha-(3-((2-(3,4-Dimethoxyphenyl)ethyl)-methylamino)propyl)-3,4-dimethoxy-alpha-(1-methylethyl)benzeneacetonitrile
alpha-Isopropyl-alpha-((N-methyl-N-homoveratryl)-gamma-aminopropyl)-3,4-dimethoxyphenylacetonitrile
cMAP_000023
delta-365
nchembio.368-comp2
nchembio.79-comp5
2
HydroxyureaapprovedPhase 2223127-07-13657
Synonyms:
1-HYDROXYUREA
127-07-1
4-03-00-00170 (Beilstein Handbook Reference)
55291_FLUKA
AC1L1GF8
AC1Q4ZXK
AI3-51139
BB_SC-7256
BRN 1741548
BSPBio_002164
Bio1_000451
Bio1_000940
Bio1_001429
Biosupressin
C07044
CCRIS 958
CHEBI:44423
CHEMBL467
CID3657
Carbamohydroxamic Acid
Carbamohydroxamic acid
Carbamohydroximic Acid
Carbamohydroximic acid
Carbamohydroxyamic Acid
Carbamohydroxyamic acid
Carbamoyl Oxime
Carbamoyl oxime
Carbamyl Hydroxamate
Carbamyl hydroxamate
Carrbamoyl Oxime
D00341
D006918
DB01005
DRG-0253
DivK1c_000556
Droxia
Droxia (TM)
Droxia (TN)
E0723DBA-5AF3-49D1-B5F6-59420AB87AC9
EINECS 204-821-7
EU-0100596
FT-0083575
H 8627
H0310
H20210
H8627_SIGMA
HMS1920F09
HMS2091L17
HMS501L18
HSDB 6887
HU
HYDREA (TN)
HYDROXY-UREA
Hidrix
Hidroxicarbamida
Hidroxicarbamida [INN-Spanish]
Hydrea
Hydrea (TM)
Hydrea, Biosupressin, Cytodrox, Hydroxyurea
Hydreia
Hydroxicarbamidum
Hydroxycarbamid
Hydroxycarbamide
Hydroxycarbamide (JAN/INN)
Hydroxycarbamidum
Hydroxycarbamidum [INN-Latin]
Hydroxycarbamine
Hydroxyharnstoff
Hydroxyharnstoff [German]
Hydroxylurea
Hydroxyurea
Hydroxyurea (D4)
Hydroxyurea (USP)
Hydroxyurea [USAN:BAN]
Hydroxyurea(d4)
 
Hydura
Hydurea
I05-0250
IDI1_000556
Idrossicarbamide
Idrossicarbamide [DCIT]
Idrossicarbamide [Dcit]
KBio1_000556
KBio2_001389
KBio2_003957
KBio2_006525
KBio3_001384
KBioGR_000383
KBioSS_001389
LS-709
Litaler
Litalir
Lopac-H-8627
Lopac0_000596
MLS001332381
MLS001332382
MLS002153389
MolMap_000029
MolPort-000-003-971
Mylocel
N-(Aminocarbonyl) Hydroxyamine
N-Carbamoylhydroxylamine
N-HYDROXY UREA
N-Hydroxymocovina
N-Hydroxymocovina [Czech]
N-Hydroxyurea
NCGC00015520-01
NCGC00015520-02
NCGC00015520-07
NCGC00093974-01
NCGC00093974-02
NCGC00093974-03
NCGC00093974-04
NCGC00093974-05
NCI C04831
NCI-C04831
NCI60_002773
NCIMech_000139
NHY
NINDS_000556
NSC 32065
NSC32065
Onco-Carbide
Onco-carbide
Oncocarbide
Oxyurea
S-phase/G-1 interface inhibitor
S1896_Selleck
SK 22591
SMR000059149
SPBio_000247
SPECTRUM1500344
SQ 1089
SQ-1089
Siklos
Spectrum2_000064
Spectrum3_000462
Spectrum4_000012
Spectrum5_000836
Spectrum_000909
Sterile Urea
TL8000673
UNII-X6Q56QN5QC
Ureaphil
WLN: ZVMQ
carbamide oxide
hydroxyaminomethanamide
hydroxyurea
nchembio.573-comp3
nchembio.90-comp4
nchembio749-comp3
tetratogen: inhibits ribonucleoside diphosphate reductase
3calcium channel blockersPhase 21985
4Vasodilator AgentsPhase 23543
5Nucleic Acid Synthesis InhibitorsPhase 24962
6Anti-Arrhythmia AgentsPhase 23093
7Calcium, DietaryPhase 25713

Interventional clinical trials:

idNameStatusNCT IDPhase
1Combination of Hydroxyurea and Verapamil for Refractory MeningiomasCompletedNCT00706810Phase 2
2Assessing Blood Pressure Remotely in Childhood Cancer SurvivorsCompletedNCT02476162

Search NIH Clinical Center for Malignant Essential Hypertension

Genetic Tests for Malignant Essential Hypertension

About this section

Anatomical Context for Malignant Essential Hypertension

About this section

Publications for Malignant Essential Hypertension

About this section

Articles related to Malignant Essential Hypertension:

(show all 13)
idTitleAuthorsYear
1
Human leukocyte antigens and malignant essential hypertension. (9657633)
1998
2
Does non-malignant essential hypertension cause renal damage? A clinician's view. (9004097)
1996
3
Urinary kallikrein excretion is low in malignant essential hypertension. (1325521)
1992
4
Renal haemodynamics and comparative effects of captopril in patients with benign- or malignant-essential hypertension, or with chronic renal failure. (3301082)
1987
5
Predisposing factors for the development of malignant essential hypertension. (3662703)
1987
6
Prospective measurement of glomerular filtration rate and effective renal plasma flow during treatment of malignant essential hypertension. (6494086)
1984
7
Renal function as an indicator of prognosis in malignant essential hypertension. (7089493)
1982
8
Immunological changes in patients with previous malignant essential hypertension. (6110039)
1981
9
Vascular lesions of malignant essential hypertension. (5567174)
1971
10
Vascular lesions of malignant essential hypertension. (5567956)
1971
11
Vascular lesions of malignant essential hypertension. (5504381)
1970
12
Successful twin pregnancy after treatment of malignant essential hypertension. (13572832)
1958
13
Clinicopathologic conference; generalized arteriosclerosis; malignant essential hypertension with dissecting aneurysm of the artery and coronary occlusion. (15426209)
1950

Variations for Malignant Essential Hypertension

About this section

Expression for genes affiliated with Malignant Essential Hypertension

About this section
Search GEO for disease gene expression data for Malignant Essential Hypertension.

Pathways for genes affiliated with Malignant Essential Hypertension

About this section

Pathways related to Malignant Essential Hypertension according to GeneCards Suite gene sharing:

idSuper pathwaysScoreTop Affiliating Genes
1
Show member pathways
8.4ACE, AGTR2, KNG1, REN

GO Terms for genes affiliated with Malignant Essential Hypertension

About this section

Cellular components related to Malignant Essential Hypertension according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1blood microparticleGO:00725629.9HBB, HBD, KNG1
2hemoglobin complexGO:00058339.8HBB, HBD
3extracellular regionGO:00055767.2ACE, AGTR2, HBB, KLK4, KLKB1, KNG1

Biological processes related to Malignant Essential Hypertension according to GeneCards Suite gene sharing:

(show all 14)
idNameGO IDScoreTop Affiliating Genes
1oxygen transportGO:001567110.5HBB, HBD
2blood coagulation, intrinsic pathwayGO:000759710.3KLKB1, KNG1
3renin-angiotensin regulation of aldosterone productionGO:000201810.2AGTR2, REN
4blood vessel remodelingGO:000197410.1ACE, AGTR2
5angiotensin maturationGO:000200310.0ACE, REN
6beta-amyloid metabolic processGO:005043510.0ACE, REN
7antigen processing and presentation of peptide antigen via MHC class IGO:000247410.0ACE, HLA-A
8regulation of blood vessel sizeGO:00508809.9HBB, KNG1
9regulation of vasodilationGO:00423129.7ACE, AGTR2
10blood coagulationGO:00075969.6HBB, HBD, KLKB1, KNG1
11vasodilationGO:00423119.6AGTR2, KNG1
12inflammatory responseGO:00069549.5AGTR2, KLKB1, KNG1, TNFRSF25
13regulation of blood pressureGO:00082179.1ACE, AGTR2, HBB, REN
14proteolysisGO:00065088.8ACE, ENSG00000264813, KLK4, KLKB1, REN

Molecular functions related to Malignant Essential Hypertension according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1oxygen transporter activityGO:000534410.4HBB, HBD
2heme bindingGO:002003710.3HBB, HBD, KLKB1
3iron ion bindingGO:000550610.2HBB, HBD, KLKB1
4peptidyl-dipeptidase activityGO:00082419.1ACE, ENSG00000264813
5peptidase activityGO:00082338.3ACE, ENSG00000264813, KLK4, KLKB1, REN
6hydrolase activityGO:00167878.1ACE, ARSE, ENSG00000264813, KLK4, KLKB1, REN

Sources for Malignant Essential Hypertension

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet